Bristol-myers Drug Patent Portfolio
Bristol-myers owns 4 orange book drugs protected by 60 US patents Given below is the list of Bristol-myers's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11400092 | Methods of treating myeloproliferative disorders | 24 Sep, 2039 | Active |
| US9511046 | Methods of treating pancreatic cancer | 12 Jul, 2034 | Active |
| US9511046 | Methods of treating pancreatic cancer | 12 Jan, 2034 | Active |
| US9393318 | Methods of treating cancer | 04 Sep, 2032 | Active |
| US9597409 | Methods of treating cancer | 04 Sep, 2032 | Active |
| US10391094 | Compositions and methods for treating myelofibrosis | 04 Jun, 2032 | Active |
| US9393318 | Methods of treating cancer | 04 Mar, 2032 | Active |
| US9597409 | Methods of treating cancer | 04 Mar, 2032 | Active |
| US7528143 | Bi-aryl meta-pyrimidine inhibitors of kinases | 16 Nov, 2031 | Active |
| US8138199 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | 30 Jun, 2028 | Active |
| US8034375 | Combinations and modes of administration of therapeutic agents and combination therapy | 13 Feb, 2027 | Active |
| US7825246 | Bi-aryl meta-pyrimidine inhibitors of kinases | 16 Dec, 2026 | Active |
| US7758891 | Combinations and modes of administration of therapeutic agents and combination therapy | 21 Aug, 2026 | Active |
| US8268348 | Combinations and modes of administration of therapeutic agents and combination therapy | 21 Aug, 2026 | Active |
| US9101543 | Combinations and modes of administration of therapeutic agents and combination therapy | 21 Aug, 2026 | Active |
| US8034375 | Combinations and modes of administration of therapeutic agents and combination therapy | 13 Aug, 2026 | Active |
| US7758891 | Combinations and modes of administration of therapeutic agents and combination therapy | 21 Feb, 2026 | Active |
| US8268348 | Combinations and modes of administration of therapeutic agents and combination therapy | 21 Feb, 2026 | Active |
| US9101543 | Combinations and modes of administration of therapeutic agents and combination therapy | 21 Feb, 2026 | Active |
| US7820788 | Compositions and methods of delivery of pharmacological agents | 27 Apr, 2025 | Active |
| US7820788 | Compositions and methods of delivery of pharmacological agents | 27 Oct, 2024 | Expired |
| US7923536 | Compositions and methods of delivery of pharmacological agents | 09 Jun, 2024 | Expired |
| US8138229 | Compositions and methods of delivery of pharmacological agents | 09 Jun, 2024 | Expired |
| US8314156 | Compositions and methods of delivery of pharmacological agents | 09 Jun, 2024 | Expired |
| US7923536 | Compositions and methods of delivery of pharmacological agents | 09 Dec, 2023 | Expired |
| US8138229 | Compositions and methods of delivery of pharmacological agents | 09 Dec, 2023 | Expired |
| US8314156 | Compositions and methods of delivery of pharmacological agents | 09 Dec, 2023 | Expired |
| US7230012 | Pharmaceutical compositions and dosage forms of thalidomide | 09 Dec, 2023 | Expired |
| US7608280 | Method of producing FR901228 | 22 Aug, 2021 | Expired |
| US7611724 | Method of producing FR901228 | 22 Aug, 2021 | Expired |
| US8853260 | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof | 10 Apr, 2021 | Expired |
| US6315720 | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug | 23 Oct, 2020 | Expired |
| US6561977 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US6755784 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US6869399 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US7141018 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US7959566 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US8315886 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US8626531 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US8853260 | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof | 10 Oct, 2020 | Expired |
| US6045501 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US6561976 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US6908432 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US7874984 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US8204763 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US8589188 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US7435745 | Methods and compositions for inhibition of angiogenesis | 03 Nov, 2017 | Expired |
| USRE41884 | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions | 14 Aug, 2016 | Expired |
| US5629327 | Methods and compositions for inhibition of angiogenesis | 13 May, 2014 | Expired |
| US4977138 | FR901228 substance and preparation thereof | 22 Aug, 2013 | Expired |
| US5498421 | Composition useful for in vivo delivery of biologics and methods employing same | 12 Mar, 2013 | Expired |
| US6235756 | Methods and compositions for inhibition of angiogenesis by thalidomide | 01 Mar, 2013 | Expired |
| US7723361 | Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide | 01 Mar, 2013 | Expired |
| US8143283 | Methods for treating blood-born tumors with thalidomide | 01 Mar, 2013 | Expired |
| US5439686 | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor | 22 Feb, 2013 | Expired |
| US6096331 | Methods and compositions useful for administration of chemotherapeutic agents | 22 Feb, 2013 | Expired |
| US6506405 | Methods and formulations of cremophor-free taxanes | 22 Feb, 2013 | Expired |
| US6537579 | Compositions and methods for administration of pharmacologically active compounds | 22 Feb, 2013 | Expired |
| US6749868 | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof | 22 Feb, 2013 | Expired |
| US6753006 | Paclitaxel-containing formulations | 22 Feb, 2013 | Expired |
Latest Legal Activities on Bristol-myers's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bristol-myers.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 08 Jul, 2024 | US8314156 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 May, 2024 | US9511046 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Mar, 2024 | US8268348 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jan, 2024 | US9393318 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Sep, 2023 | US8138199 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Sep, 2023 | US8138229 (Litigated) |
|
Expire Patent
Critical
| 17 Jul, 2023 | US7959566 |
|
Patent Term Extension Certificate
Critical
| 25 May, 2023 | US7528143 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 Mar, 2023 | US8034375 |
|
Withdrawal of Application for PTE
Critical
| 27 Feb, 2023 | US8138199 |
|
Withdrawal of Application for PTE
Critical
| 27 Feb, 2023 | US7825246 |
|
Expire Patent
Critical
| 27 Feb, 2023 | US7874984 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Feb, 2023 | US10391094 |
|
Maintenance Fee Reminder Mailed
Critical
| 30 Jan, 2023 | US7959566 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jan, 2023 | US9101543 |
Bristol-myers's Drug Patent Litigations
Bristol-myers's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 23, 2015, against patent number US6315720. The petitioner Coalition for Affordable Drugs VI LLC, challenged the validity of this patent, with Celgene Corporation as the respondent. Click below to track the latest information on how companies are challenging Bristol-myers's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7820788 | November, 2017 |
Terminated-Settled
(13 Jul, 2018)
| Abraxis BioScience, LLC | Apotex Inc. |
| US7923536 | November, 2017 |
Terminated-Settled
(13 Jul, 2018)
| Abraxis Biosciences, LLC | Apotex Inc. |
| US8138229 | November, 2017 |
Terminated
(13 Jul, 2018)
| Abraxis BioScience, LLC et al. | Apotex Inc. et al. |
| US7820788 | April, 2017 |
Terminated-Settled
(08 May, 2018)
| ABRAXIS BIOSCIENCE, LLC | Actavis LLC |
| US7820788 | November, 2017 |
Terminated-Denied
(08 May, 2018)
| Abraxis Biosciences, LLC | Cipla Ltd. |
| US7923536 | April, 2017 |
Terminated-Settled
(08 May, 2018)
| ABRAXIS BIOSCIENCE, LLC | Actavis LLC |
| US7923536 | November, 2017 |
Terminated-Denied
(08 May, 2018)
| Abraxis Biosciences, LLC | Cipla Ltd. |
| US8138229 | April, 2017 |
Terminated-Settled
(08 May, 2018)
| ABRAXIS BIOSCIENCE, LLC, | Actavis LLC |
| US8138229 | November, 2017 |
Terminated-Denied
(08 May, 2018)
| AbraxisBiosciences, LLC | Cipla Ltd. |
| US8853260 | April, 2017 |
Terminated-Denied
(11 Oct, 2017)
| ABRAXIS BIOSCIENCE, LLC | Actavis LLC |
| US6045501 | April, 2015 |
Final Written Decision
(26 Oct, 2016)
| Celgene Corporation | Coalition For Affordable Drugs VI LLC |
| US6315720 | April, 2015 |
FWD Entered
(26 Oct, 2016)
| Celgene Corporation | Coalition for Affordable Drugs VI LLC |
Bristol-myers Drug Patents' Oppositions Filed in EPO
Bristol-myers drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 01, 2012, by Generics [Uk] Limited. This opposition was filed on patent number EP06735710A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP14737791A | Feb, 2022 | Accord Healthcare | Revoked |
| EP14737791A | Feb, 2022 | Teva Pharmaceutical Industries Ltd. | Revoked |
| EP14737791A | Jan, 2022 | Generics [UK] Limited | Revoked |
| EP17165979A | Apr, 2020 | Generics (UK) Ltd | Revoked |
| EP17165979A | Apr, 2020 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP03799876A | Mar, 2019 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP03799876A | Mar, 2019 | Wittkopp, Alexander | Revoked |
| EP11763292A | Jun, 2017 | Generics (UK) Ltd | Revoked |
| EP11763292A | Jun, 2017 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP06735710A | Aug, 2012 | MediGene Aktiengesellschaft | Revoked |
| EP06735710A | Aug, 2012 | Generics [UK] Limited | Revoked |
Bristol-myers's Family Patents
Bristol-myers drugs have patent protection in a total of 43 countries. It's US patent count contributes only to 20.1% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Bristol-myers Drug List
Given below is the complete list of Bristol-myers's drugs and the patents protecting them.
1. Abraxane
Abraxane is protected by 32 patents, out of which 17 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9511046
(Pediatric)
| Methods of treating pancreatic cancer |
12 Jul, 2034
(9 years from now)
| Active |
| US9511046 | Methods of treating pancreatic cancer |
12 Jan, 2034
(9 years from now)
| Active |
| US9393318
(Pediatric)
| Methods of treating cancer |
04 Sep, 2032
(7 years from now)
| Active |
| US9597409
(Pediatric)
| Methods of treating cancer |
04 Sep, 2032
(7 years from now)
| Active |
| US9393318 | Methods of treating cancer |
04 Mar, 2032
(7 years from now)
| Active |
| US9597409 | Methods of treating cancer |
04 Mar, 2032
(7 years from now)
| Active |
| US8034375
(Pediatric)
| Combinations and modes of administration of therapeutic agents and combination therapy |
13 Feb, 2027
(2 years from now)
| Active |
| US7758891
(Pediatric)
| Combinations and modes of administration of therapeutic agents and combination therapy |
21 Aug, 2026
(1 year, 9 months from now)
| Active |
| US8268348
(Pediatric)
| Combinations and modes of administration of therapeutic agents and combination therapy |
21 Aug, 2026
(1 year, 9 months from now)
| Active |
| US9101543
(Pediatric)
| Combinations and modes of administration of therapeutic agents and combination therapy |
21 Aug, 2026
(1 year, 9 months from now)
| Active |
| US8034375 | Combinations and modes of administration of therapeutic agents and combination therapy |
13 Aug, 2026
(1 year, 8 months from now)
| Active |
| US7758891 | Combinations and modes of administration of therapeutic agents and combination therapy |
21 Feb, 2026
(1 year, 3 months from now)
| Active |
| US8268348 | Combinations and modes of administration of therapeutic agents and combination therapy |
21 Feb, 2026
(1 year, 3 months from now)
| Active |
| US9101543 | Combinations and modes of administration of therapeutic agents and combination therapy |
21 Feb, 2026
(1 year, 3 months from now)
| Active |
| US7820788
(Pediatric)
| Compositions and methods of delivery of pharmacological agents |
27 Apr, 2025
(5 months from now)
| Active |
| US7820788 | Compositions and methods of delivery of pharmacological agents |
27 Oct, 2024
(19 days ago)
| Expired |
| US7923536
(Pediatric)
| Compositions and methods of delivery of pharmacological agents |
09 Jun, 2024
(5 months ago)
| Expired |
| US8138229
(Pediatric)
| Compositions and methods of delivery of pharmacological agents |
09 Jun, 2024
(5 months ago)
| Expired |
| US8314156
(Pediatric)
| Compositions and methods of delivery of pharmacological agents |
09 Jun, 2024
(5 months ago)
| Expired |
| US7923536 | Compositions and methods of delivery of pharmacological agents |
09 Dec, 2023
(11 months ago)
| Expired |
| US8138229 | Compositions and methods of delivery of pharmacological agents |
09 Dec, 2023
(11 months ago)
| Expired |
| US8314156 | Compositions and methods of delivery of pharmacological agents |
09 Dec, 2023
(11 months ago)
| Expired |
| US8853260
(Pediatric)
| Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
10 Apr, 2021
(3 years ago)
| Expired |
| US8853260 | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
10 Oct, 2020
(4 years ago)
| Expired |
| USRE41884 | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
14 Aug, 2016
(8 years ago)
| Expired |
| US5498421 | Composition useful for in vivo delivery of biologics and methods employing same |
12 Mar, 2013
(11 years ago)
| Expired |
| US5439686 | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
22 Feb, 2013
(11 years ago)
| Expired |
| US6096331 | Methods and compositions useful for administration of chemotherapeutic agents |
22 Feb, 2013
(11 years ago)
| Expired |
| US6506405 | Methods and formulations of cremophor-free taxanes |
22 Feb, 2013
(11 years ago)
| Expired |
| US6537579 | Compositions and methods for administration of pharmacologically active compounds |
22 Feb, 2013
(11 years ago)
| Expired |
| US6749868 | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
22 Feb, 2013
(11 years ago)
| Expired |
| US6753006 | Paclitaxel-containing formulations |
22 Feb, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Abraxane's drug page
2. Inrebic
Inrebic is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11400092 | Methods of treating myeloproliferative disorders |
24 Sep, 2039
(14 years from now)
| Active |
| US10391094 | Compositions and methods for treating myelofibrosis |
04 Jun, 2032
(7 years from now)
| Active |
| US7528143 | Bi-aryl meta-pyrimidine inhibitors of kinases |
16 Nov, 2031
(7 years from now)
| Active |
| US8138199 | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
30 Jun, 2028
(3 years from now)
| Active |
| US7825246 | Bi-aryl meta-pyrimidine inhibitors of kinases |
16 Dec, 2026
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inrebic's drug page
3. Istodax
Istodax is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7608280 | Method of producing FR901228 |
22 Aug, 2021
(3 years ago)
| Expired |
| US7611724 | Method of producing FR901228 |
22 Aug, 2021
(3 years ago)
| Expired |
| US4977138 | FR901228 substance and preparation thereof |
22 Aug, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Istodax's drug page
4. Thalomid
Thalomid is protected by 20 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7230012 | Pharmaceutical compositions and dosage forms of thalidomide |
09 Dec, 2023
(11 months ago)
| Expired |
| US6315720 | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
23 Oct, 2020
(4 years ago)
| Expired |
| US6561977 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US6755784 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US6869399 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US7141018 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US7959566 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US8315886 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US8626531 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US6045501 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US6561976 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US6908432 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US7874984 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US8204763 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US8589188 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US7435745 | Methods and compositions for inhibition of angiogenesis |
03 Nov, 2017
(7 years ago)
| Expired |
| US5629327 | Methods and compositions for inhibition of angiogenesis |
13 May, 2014
(10 years ago)
| Expired |
| US6235756 | Methods and compositions for inhibition of angiogenesis by thalidomide |
01 Mar, 2013
(11 years ago)
| Expired |
| US7723361 | Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide |
01 Mar, 2013
(11 years ago)
| Expired |
| US8143283 | Methods for treating blood-born tumors with thalidomide |
01 Mar, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Thalomid's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List